[1] Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61:69-90.
[2] Hong YF, Chen ZH, Ma XK, et al. Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma.Tumour Biol, 2016, 4:5265-5273.
[3] Zhang TT, Zhao XQ, Liu Z, et al. Factors affecting the recurrence and survival of hepatocellular carcinoma after hepatectomy: a retrospective study of 601 Chinese patients. Clin Transl Oncol, 2015, Nov 17(Epub ahead of print).
[4] Harding JJ, El Dika I, Abou-Alfa GK. Immunotherapy in hepatocellular carcinoma: Primed to make a difference Cancer, 2016, 122:367-377.
[5] Yuan CH, Sun XM, Zhu CL, et al. Amphiregulin activates regulatory Tlymphocytes and suppresses CD8+T cell-mediated anti-tumor response in hepatocellular carcinoma cells. Oncotarget, 2015, 6:32138-32153.
[6] Lin ZX, Ruan DY, Li Y, et al. Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection.World J Gastroenterol, 2015, 21:10898-10906.
[7] Müller P, Rothschild SI, Arnold W, et al. Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. Cancer Immunol Immunother, 2016, 65:1-11.
[8] Jia W, Wu J, Jia H, et al. The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients. PLoS One, 2015, 10:e0143061.
[9] Jang M, Yew PY, Hasegawa K, et al. Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. Oncoimmunology, 2015 ,4:e1030561.
[10] Jian-Hui C, Iskandar EA, Cai SI, et al. Significance of Onodera's prognostic nutritional index in patients with colorectal cancer: a large cohort study in a single Chinese institution. Tumour Biol, 2016, 37:3277-3283.
[11] Kun L, Tang L, Wang J, et al. Effect of Combined General/Epidural Anesthesia on Postoperative NK Cell Activity and Cytokine Response in Gastric Cancer Patients Undergoing Radical Resection. Hepatogastroenterology, 2014 ,61:1142-1147.
[12] Han Y, Li H, Guan Y, et al. Immune repertoire: A potential biomarker and therapeutic for hepatocellular carcinoma. Cancer Lett, 2015, July 15(Epub ahead of print).
[13] Bertoletti A, Brunetto M, Maini MK, et al. T cell receptor-therapy in HBV-related hepatocellular carcinoma.Onco immunology, 2015, 4:e1008354. |
